Human FGF-19 is encoded by the FGF19 gene. FGF-19 belongs to the FGF-19 subfamily which has three members FGF-19, 21, 23. FGFs are classically considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis. By contrast, the FGF-19 subfamily has recently been shown to function in an endocrine manner. Members of this subfamily have poor ability of binding to heparin binding site which is a crucial factor in ligand-receptor complex formation. β-Klotho has been identified as co-factor required for FGF-19, 21, 23 signaling. It can obviously increase ligand-receptor affinity. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4. In FGF-19 transgenic mice, reducing liver triglycerides, increasing fatty acid oxidation, reducing glucose levels and improving insulin sensitivity can be observed.
Reference:
1. Ladher RK, Anakwe KU, Gurney AL, et al. 2000. Science. 290:1965-7
2. Tomlinson E, Fu L, John L, et al. 2002. Endocrinology. 143:1741-7
3. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 1996. Proc Natl Acad Sci U S A. 93:9850-7
4. Fu L, John LM, Adams SH, et al. 2004. Endocrinology. 145:2594-603
5. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35
6. Kurosu H, Kuro OM. 2009. Mol Cell Endocrinol. 299:72-8
7. Lin BC, Wang M, Blackmore C, et al. 2007. J Biol Chem. 282:27277-84
8. Kharitonenkov A, Dunbar JD, Bina HA, et al. 2008. J Cell Physiol. 215:1-7.